Medrx Co

Medrx Co CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Medrx Co (4586.T) as of Nov 19, 2026 is -9.32 %. In the previous year, CapEx to Operating Cash Flow Ratio was -0.03 % — a change of 28,134.62% (lower).

CapEx/OCF

-9.32 %

YoY

28,134.62%

Last updated:

CapEx to Operating Cash Flow Ratio of Medrx Co is 2025 -9.32 % . CapEx to Operating Cash Flow Ratio of Medrx Co was 2024 -0.03 % . It decreases by 28,134.62% lower compared to the previous year.

The Medrx Co CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
-3.37 JPY
Jan 1, 2019
-16.33 JPY
Jan 1, 2020
-4.00 JPY
Jan 1, 2021
-0.28 JPY
Jan 1, 2022
-0.18 JPY
Jan 1, 2023
-0.08 JPY
Jan 1, 2024
-0.03 JPY
Jan 1, 2025
-9.32 JPY
The Medrx Co CapEx/OCF history
YEARCapEx/OCFYoY
-9.32 %+28,134.62%
-0.03 %-60.30%
-0.08 %-54.43%
-0.18 %-33.71%
-0.28 %-93.12%
-4.00 %-75.51%
-16.33 %+384.81%
-3.37 %-43.01%
-5.91 %+944.07%
-0.57 %-88.47%
-4.91 %-58.51%
-11.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

CapEx to Operating Cash Flow Ratio of Medrx Co is -9.32 % in 2025.

CapEx to Operating Cash Flow Ratio of Medrx Co changed from -0.03 % to -9.32 %, representing a 28,134.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Medrx Co since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Medrx Co with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Medrx Co

All Key Metrics — Medrx Co